心房颤动及相关疾病外科治疗提供商AtriCure公司（股票代码：ATRC）夜盘股价大涨10.56%，主要受益于公司发布的超预期第二季度财报以及上调全年业绩展望。
据悉，AtriCure第二季度每股亏损为0.13美元，优于分析师预期的0.17美元亏损。公司收入同比增长17.1%至1.361亿美元，超过了市场预期的1.3017亿美元。这一强劲表现主要得益于公司产品组合的广泛应用，特别是其AtriClip平台和cryoSPHERE设备的出色表现。值得注意的是，公司在美国市场的收入增长15.7%至1.106亿美元，而国际收入更是增长23.3%至2560万美元。
基于强劲的季度业绩，AtriCure上调了2025财年全年指引，预计全年收入将达到5.27亿美元至5.33亿美元之间，高于此前分析师预期的5.23亿美元。公司还改善了全年调整后每股亏损预期至0.39美元至0.34美元之间，优于分析师预期的0.51美元亏损。AtriCure总裁兼首席执行官Michael Carrel表示："我们的出色业绩反映了创新的力量和不断扩大的产品组合带来的影响。随着我们的新技术推动更深入的应用、缩短手术时间并改善患者预后，我们看到了越来越强劲的发展势头。"这一积极展望无疑增强了投资者对公司未来发展的信心，推动了股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.